Skip to main content

Advertisement

SpringerLink
Log in

Hepatic porphyria: A narrative review

  • Review Article
  • Published:
Indian Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Porphyrias are a group of metabolic disorders, which result from a specific abnormality in one of the eight enzymes of the heme biosynthetic pathway. These have been subdivided based on the predominant site of enzyme defect into hepatic and erythropoietic types and based on clinical presentation into acute neurovisceral and cutaneous blistering porphyrias. This review focuses on hepatic porphyrias, which include acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), aminolevulinic acid dehydratase deficiency porphyria (ADP), and porphyria cutanea tarda (PCT). Of these, AIP and ADP are classified as acute porphyria, PCT as cutaneous, while VP and HCP present with both acute and cutaneous clinical manifestations. Porphobilinogen levels in a spot urine sample is the initial screening test for the diagnosis of acute hepatic porphyria, and plasma with spot urine porphyrin levels is the initial screening test to approach patients suspected of cutaneous porphyria. Specific biochemical porphyrin profile for each porphyria helps in determining the specific diagnosis. Pain relief and elimination of triggering agents are the initial steps in managing a patient presenting with an acute attack. Intravenous glucose administration terminates the mild episode of acute porphyria, with intravenous hemin needed for management of moderate to severe episodes. Liver transplantation is curative and may be needed for patients with a life-threatening acute porphyria attack or for patients with recurrent acute attacks refractory to prophylactic treatment. Of the cutaneous porphyrias, PCT is the most common and is frequently associated with a combination of multiple susceptibility factors such as alcohol use, smoking, hepatitis C virus infection, HIV infection, estrogen use, and mutations of the hemochromatosis gene. Regular phlebotomy schedule and low-dose hydroxychloroquine are effective and safe treatment options for management of PCT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Karim Z, Lyoumi S, Nicolas G, Deybach JC, Gouya L, Puy H. Porphyrias: a 2015 update. Clin Res Hepatol Gastroenterol. 2015;9:412–25.

    Article  Google Scholar 

  2. Besur S, Schmeltzer P, Bonkovsky HL. Acute porphyrias. J Emerg Med. 2015;49:305–12.

    Article  PubMed  Google Scholar 

  3. Singal, AK, Anderson, KE. Variegate porphyria. In: Gene Reviews. Pagon RA, Adam MP, Ardinger HH, et al. Eds. 1993: Seattle (WA).

  4. Singal AK, Phillips J. Porphyria cutanea tarda. Handbook of Porphyrin Science. Ed. Smith KM, Kadish KM, Guilard R. Vol. 29. 2013, Singapore World Scientific Publishing Co Pte. Ltd. . 219–262.

  5. Jalil S, Grady JJ, Lee C, Anderson KE. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol 2010;8:297–302, 302 e1.

  6. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127:1233–41.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). 2005;84:48–60.

    Article  Google Scholar 

  8. Lin CS, Park SB, Krishnan AV. Porphyric neuropathy. Handb Clin Neurol. 2013;115:613–27.

    Article  PubMed  Google Scholar 

  9. Bissell DM, Lai JC, Meister RK, Blanc PD. Role of delta-aminolevulinic acid in the symptoms of acute porphyria. Am J Med. 2015;128:313–7.

    Article  CAS  PubMed  Google Scholar 

  10. Homedan C, Laafi J, Schmitt C, et al. Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. Int J Biochem Cell Biol. 2014;51:93–101.

    Article  CAS  PubMed  Google Scholar 

  11. Singal AK, Anderson KE.Variegate porphyria. In: Pagon RA, Adam MP, Ardinger HH, et al. editors. GeneReviews [Internet] Seattle (WA): University of Washington, Seattle; 1993–2016. 2013 Feb 14.

  12. Hasanoglu A, Balwani M, Kasapkara CS, et al. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis. 2011;34:225–31.

    Article  CAS  PubMed  Google Scholar 

  13. Nordmann Y, Grandchamp B, de Verneuil H, Phung L, Cartigny B, Fontaine G. Harderoporphyria: a variant hereditary coproporphyria. J Clin Invest. 1983;72:1139–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Doss MO, Stauch T, Gross U, et al. The third case of doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis. 2004;27:529–36.

    Article  CAS  PubMed  Google Scholar 

  15. Rossetti MV, Granata BX, Giudice J, Parera VE, Batlle A. Genetic and biochemical studies in Argentinean patients with variegate porphyria. BMC Med Genet. 2008;9:54.

  16. Szlendak U, Lipniacka A, Bianketti J, Podolak-Dawidziak M, Bykowska K. Porphobilinogen deaminase gene mutations in Polish patients with non-erythroid acute intermittent porphyria. Adv Clin Exp Med. 2015;24:63–8.

    Article  PubMed  Google Scholar 

  17. Sassa S, Kondo M, Taketani S, et al. Molecular defects of the coproporphyrinogen oxidase gene in hereditary coproporphyria. Cell Mol Biol (Noisy-le-grand). 1997;43:59–66.

    CAS  Google Scholar 

  18. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36:849–57.

    Article  PubMed  Google Scholar 

  19. Bissell DM, Wang B, Lai J. Hereditary coproporphyria. In: GeneReviews(R), Pagon RA, Adam MP, Ardinger HH, et al. Eds. 1993: Seattle (WA).

  20. Plewinska M, Thunell S, Holmberg L, Wetmur JG, Desnick RJ. Delta-aminolevulinate dehydratase deficient porphyria: identification of the molecular lesions in a severely affected homozygote. Am J Hum Genet. 1991;49:167–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Thunell S, Holmberg L, Lundgren J. Aminolaevulinate dehydratase porphyria in infancy. A clinical and biochemical study. J Clin Chem Clin Biochem. 1987;25:5–14.

    CAS  PubMed  Google Scholar 

  22. Fujita H, Sassa S, Lundgren J, Holmberg L, Thunell S, Kappas A. Enzymatic defect in a child with hereditary hepatic porphyria due to homozygous delta-aminolevulinic acid dehydratase deficiency: immunochemical studies. Pediatrics. 1987;80:880–5.

    CAS  PubMed  Google Scholar 

  23. Akagi R, Nishitani C, Harigae H, et al. Molecular analysis of delta-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria. Blood. 2000;96:3618–23.

    CAS  PubMed  Google Scholar 

  24. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142:439–450. Erratum in: Ann Intern Med. 2005;143:316.

  25. Ramanujam VM, Anderson KE. Porphyria diagnostics-part 1: a brief overview of the porphyrias. Curr Protoc Hum Genet. 2015;86:17.20.1–26.

    Article  Google Scholar 

  26. Ahangari A, Bckstrm T, Innala E, Andersson C, Turkmen S. Acute intermittent porphyria symptoms during the menstrual cycle. Intern Med J. 2015;45:725–31.

    Article  CAS  PubMed  Google Scholar 

  27. Collantes M, Serrano-Mendioroz I, Benito M, et al. Glucose metabolism during fasting is altered in experimental porphobilinogen deaminase deficiency. Hum Mol Genet. 2016;25:1318–27.

    Article  CAS  PubMed  Google Scholar 

  28. Bissell DM, Wang B. Acute hepatic porphyria. J Clin Transl Hepatol. 2015;3:17–26.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142:439–50.

    Article  PubMed  Google Scholar 

  30. Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120:4496–504.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Akagi R, Kato N, Inoue R, Anderson KE, Jaffe EK, Sassa S. Delta-aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab. 2006;87:329–36.

    Article  CAS  PubMed  Google Scholar 

  32. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. Am J Med. 2006;119:801. e19–24.

  33. Stein P, Badminton M, Barth J, Rees D, Stewart MF. British and Irish Porphyria Network. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50 Pt 3:217–23.

    Article  PubMed  Google Scholar 

  34. Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375:924–37.

    Article  CAS  PubMed  Google Scholar 

  35. Frei P, Minder EI, Corti N, et al. Liver transplantation because of acute liver failure due to heme arginate overdose in a patient with acute intermittent porphyria. Case Rep Gastroenterol. 2012;6:190–6.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Marsden JT, Rees DCA. Retrospective analysis of outcome of pregnancy in patients with acute porphyria. J Inherit Metab Dis. 2010;33:591–6.

    Article  PubMed  Google Scholar 

  37. Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005;122:505–15.

    Article  CAS  PubMed  Google Scholar 

  38. Chacko BK, Kramer PA, Ravi S, et al. The bioenergetic health index: a new concept in mitochondrial translational research. Clin Sci (Lond). 2014;127:367–73.

    Article  CAS  Google Scholar 

  39. Ferrer MD, Tauler P, Sureda A, Palacin C, Tur JA, Pons A. Antioxidants restore protoporphyrinogen oxidase in variegate porphyria patients. Eur J Clin Invest. 2013;43:668–78.

    Article  CAS  PubMed  Google Scholar 

  40. Singal AK, Parker C, Bowden C, Thapar M, Liu L, McGuire BM. Liver transplantation in the management of porphyria. Hepatology. 2014;60:1082–9.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Anderson KE, Spitz IM, Sassa S, Bardin CW, Kappas A. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. 1984;311:643–5.

    Article  CAS  PubMed  Google Scholar 

  42. Anderson KE, Spitz IM, Bardin CW, Kappas AA. Gonadotropin releasing hormone analogue prevents cyclical attacks of porphyria. Arch Intern Med. 1990;150:1469–74.

    Article  CAS  PubMed  Google Scholar 

  43. Dowman JK, Gunson BK, Mirza DF, et al. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. Liver Transpl. 2012;18:195–200.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Yasuda M, Erwin AL, Liu LU, et al. Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver. Mol Med. 2015;21:487–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Sullenger BA, Nair S. From the RNA world to the clinic. Science. 2016;352:1417–20.

    Article  CAS  PubMed  Google Scholar 

  46. Yasuda M, Gan L, Chen B, et al. RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice. Proc Natl Acad Sci U S A. 2014;111:7777–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Chan A, Liebow A, Yasuda M, et al. Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification. Mol Ther Nucleic Acids. 2015;4:e263.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Paneda A, Lopez-Franco E, Kaeppel C, et al. Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria. Hum Gene Ther. 2013;24:1007–17.

    Article  CAS  PubMed  Google Scholar 

  49. D'Avola D, Lopez-Franco E, Sangro B, et al. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. J Hepatol. 2016;65:776–83.

  50. Yin Z, Wahlin S, Ellis EC, Harper P, Ericzon BG, Nowak G. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria. Cell Transplant. 2014;23:1153–62.

    Article  PubMed  Google Scholar 

  51. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992;71:1–13.

    Article  CAS  Google Scholar 

  52. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201–14.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Herrero C, Badenas C, Aguilera P, To-Figueras J. Acute intermittent porphyria: long-term follow up of 35 patients. Med Clin (Barc). 2015;145:332–7.

    Article  Google Scholar 

  54. Bonkovsky HL, Guo JT, Hou W, Li T, Narang T, Thapar M. Porphyrin and heme metabolism and the porphyrias. Compr Physiol. 2013;3:365–401.

    PubMed  Google Scholar 

  55. Pallet N, Mami I, Schmitt C, et al. High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria. Kidney Int. 2015;88:386–95.

    Article  CAS  PubMed  Google Scholar 

  56. Innala E, Andersson C. Screening for hepatocellular carcinoma in acute intermittent porphyria: a 15-year follow-up in northern Sweden. J Intern Med. 2011;269:538–45.

    Article  CAS  PubMed  Google Scholar 

  57. Lang E, Schafer M, Schwender H, Neumann NJ, Frank J. Occurrence of malignant tumours in the acute hepatic porphyrias. JIMD Rep. 2015;22:17–22.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Stewart MF. Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. J Clin Pathol. 2012;65:976–80.

    Article  PubMed  Google Scholar 

  59. Sardh E, Wahlin S, Bjornstedt M, Harper P, Andersson DE. High risk of primary liver cancer in a cohort of 179 patients with acute hepatic porphyria. J Inherit Metab Dis. 2013;36:1063–71.

    Article  CAS  PubMed  Google Scholar 

  60. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Phillips JD, Bergonia HA, Reilly CA, Franklin MR, Kushner JPA. Porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2007;104:5079–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10:1402–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Darwich E, To-Figueras J, Molina-Lopez RA, et al. Increased serum hepcidin levels in patients with porphyria cutanea tarda. J Eur Acad Dermatol Venereol. 2013;27:e68–74.

    Article  CAS  PubMed  Google Scholar 

  64. Frank J, Poblete-Gutierrez P. Porphyria cutanea tarda—when skin meets liver. Best Pract Res Clin Gastroenterol. 2010;24:735–45.

    Article  CAS  PubMed  Google Scholar 

  65. Maynard B, Peters MS. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol. 1992;19:40–7.

    Article  CAS  PubMed  Google Scholar 

  66. Lim HW, Poh-Fitzpatrick MB. Hepatoerythropoietic porphyria: a variant of childhood-onset porphyria cutanea tarda. Porphyrin profiles and enzymatic studies of two cases in a family. J Am Acad Dermatol. 1984;11:1103–11.

    Article  CAS  PubMed  Google Scholar 

  67. Boudghene-Stambouli O, Merad-Boudia A. Hepato-erythropoietic porphyria. Ann Dermatol Venereol. 1995;122:615–7.

    CAS  PubMed  Google Scholar 

  68. Schulenburg-Brand D, Katugampola R, Anstey AV, Badminton MN. The cutaneous porphyrias. Dermatol Clin. 2014;32:369–84 ix.

    Article  CAS  PubMed  Google Scholar 

  69. Ippen H. Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol. 1977;14:253–9.

    CAS  PubMed  Google Scholar 

  70. Stolzel U, Kostler E, Schuppan D, et al. Hemochromatosis (HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol. 2003;139:309–13.

    Article  PubMed  Google Scholar 

  71. Miyauchi S, Shiraishi S, Miki Y. Small volume plasmapheresis in the management of porphyria cutanea tarda. Arch Dermatol. 1983;119:752–5.

    Article  CAS  PubMed  Google Scholar 

  72. Poux JM, Demontis R, Cadranel JF, Ghazali A, Fievet P, Nordmann Y. Porphyria cutanea tarda in a dialyzed patient with hepatitis C virus infection: dramatic efficacy of small repeated phlebotomies. Am J Med. 1997;103:163–4.

    CAS  PubMed  Google Scholar 

  73. Vasconcelos P, Luz-Rodrigues H, Santos C, Filipe P. Desferrioxamine treatment of porphyria cutanea tarda in a patient with HIV and chronic renal failure. Dermatol Ther. 2014;27:16–8.

    Article  PubMed  Google Scholar 

  74. Ryan Caballes F, Sendi H, Bonkovsky HL, Hepatitis C. Porphyria cutanea tarda and liver iron: an update. Liver Int. 2012;32:880–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Hisamuddin K, Veluru C, Mullen KD. Skin lesions in a patient on therapy for chronic hepatitis. Clin Gastroenterol Hepatol. 2009;7:A24C.

    Article  Google Scholar 

  76. Dedania B, Wu GY. Dermatologic extrahepatic manifestations of hepatitis C. J Clin Transl Hepatol. 2015;3:127–33.

    PubMed  PubMed Central  Google Scholar 

  77. Singal AKGE, Gou E, Albuerne M, Hallberg CK, Anderson KEA. Relapse of PCT after achieving remission with phlebotomy or low dose hydroxychloroquine. Hepatology. 2013;58:299A.

  78. Fracanzani AL, Taioli E, Sampietro M, et al. Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease. J Hepatol. 2001;35:498–503.

    Article  CAS  PubMed  Google Scholar 

  79. Tollanes MC, Aarsand AK, Sandberg S. Risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. J Inherit Metab Dis. 2011;34:217–23.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by grant funding U54DK083909 to the Porphyria Consortium, a part of the NIH Rare Diseases Clinical Research Network, supported through collaboration between the NIH office of Rare Diseases Research at the National Center for Advancing Translational Science and the National Institute of Diabetes and Digestive and Kidney Diseases.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, UAB University of Alabama in Birmingham, Birmingham, AL, USA

    Sumant Arora, Steven Young, Sudha Kodali & Ashwani K. Singal

  2. Division of Gastroenterology and Hepatology, UAB University of Alabama in Birmingham, Birmingham, AL, USA

    Sudha Kodali & Ashwani K. Singal

Authors
  1. Sumant Arora
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sudha Kodali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ashwani K. Singal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashwani K. Singal.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arora, S., Young, S., Kodali, S. et al. Hepatic porphyria: A narrative review. Indian J Gastroenterol 35, 405–418 (2016). https://doi.org/10.1007/s12664-016-0698-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12664-016-0698-0

Keywords

Search

Navigation